Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Aditxt is a biotechnology business based in the US. Aditxt shares (ADTX) are listed on the NASDAQ and all prices are listed in US Dollars. Aditxt employs 58 staff and has a trailing 12-month revenue of around $853,153.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $1.36 |
|---|---|
| 52-week range | $1.00 - $28.49 |
| 50-day moving average | $1.52 |
| 200-day moving average | $7.28 |
| Wall St. target price | $27.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.72 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.36 from 2023-01-27
| 1 week (2023-01-23) | -12.26% |
|---|---|
| 1 month (2022-12-30) | 17.79% |
| 3 months (2022-10-28) | -49.25% |
| 6 months (2022-07-29) | 760.76% |
| 1 year (2022-01-26) | N/A |
|---|---|
| 2 years (2021-01-29) | -63.54% |
| 3 years (2020-01-26) | N/A |
| 5 years (2018-01-26) | N/A |
| Revenue TTM | $853,153 |
|---|---|
| Gross profit TTM | $27,055 |
| Return on assets TTM | -86.33% |
| Return on equity TTM | -339.11% |
| Profit margin | 0% |
| Book value | $3.40 |
| Market capitalisation | $6.5 million |
TTM: trailing 12 months
We're not expecting Aditxt to pay a dividend over the next 12 months.
Aditxt's shares were split on a 1:50 basis on 13 September 2022. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aditxt shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Aditxt shares which in turn could have impacted Aditxt's share price.
Over the last 12 months, Aditxt's shares have ranged in value from as little as $1 up to $28.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aditxt's is 1.4726. This would suggest that Aditxt's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aditxt, Inc. , a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
